613 related articles for article (PubMed ID: 20307399)
1. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
2. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):382-90. PubMed ID: 20307400
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. 10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA
N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090
[TBL] [Abstract][Full Text] [Related]
5. Glucose control and vascular complications in veterans with type 2 diabetes.
Duckworth W; Abraira C; Moritz T; Reda D; Emanuele N; Reaven PD; Zieve FJ; Marks J; Davis SN; Hayward R; Warren SR; Goldman S; McCarren M; Vitek ME; Henderson WG; Huang GD;
N Engl J Med; 2009 Jan; 360(2):129-39. PubMed ID: 19092145
[TBL] [Abstract][Full Text] [Related]
6. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
7. After avandia: the use of antidiabetic drugs in patients with heart failure.
Khalaf KI; Taegtmeyer H
Tex Heart Inst J; 2012; 39(2):174-8. PubMed ID: 22740727
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
Seufert J; Lübben G; Dietrich K; Bates PC
Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
[TBL] [Abstract][Full Text] [Related]
9. Intensive glycemic control and cardiovascular disease: an update.
Brown A; Reynolds LR; Bruemmer D
Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
[TBL] [Abstract][Full Text] [Related]
10. The effect of intensive glycaemic control on cardiovascular outcomes.
Hill D; Fisher M
Diabetes Obes Metab; 2010 Aug; 12(8):641-7. PubMed ID: 20590740
[TBL] [Abstract][Full Text] [Related]
11. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
[TBL] [Abstract][Full Text] [Related]
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
[TBL] [Abstract][Full Text] [Related]
13. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
Macisaac RJ; Jerums G
Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
[TBL] [Abstract][Full Text] [Related]
14. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
15. Treating diabetes today with gliclazide MR: a matter of numbers.
Avogaro A
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():14-9. PubMed ID: 22118706
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
17. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
18. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
20. Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
Boussageon R; Gueyffier F; Cornu C
Diabetes Metab; 2014 Jun; 40(3):169-75. PubMed ID: 24503191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
